Investor
Merck & Co., Inc.
CIK 0000310158 · filed 2026-05-13 · SEC filing
13F book
$349.4M
Positions
14
3 new · 1 sold
Largest name
33.6%
Moderna, Inc. · MRNA
Est. mark
$38.5M
Price effect on 11 names still held. Flow $34.6M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Moderna, Inc. | MRNA | 2.31M | $117.3M | 33.6% | $49.2M | Held |
| Personalis, Inc. | PSNL | 14M | $89.5M | 25.6% | −$22.3M | Held |
| Kymera Therapeutics, Inc. | KYMR | 772.2K | $64.3M | 18.4% | $4.23M | Held |
| Entrada Therapeutics, Inc. | TRDA | 1.74M | $22M | 6.3% | $4.07M | Held |
| Eikon Therapeutics, Inc. | EIKN | 1.67M | $17.6M | 5.0% | — | New |
| Aktis Oncology, Inc. | AKTS | 952.8K | $17M | 4.9% | — | New |
| Alector, Inc. | ALEC | 3.55M | $7.62M | 2.2% | $2.09M | Held |
| Sutro Biopharma, Inc. | STRO | 272.4K | $6.78M | 1.9% | $3.63M | Held |
| Evaxion Biotech A/S | — | 1.21M | $4.52M | 1.3% | −$1.27M | Held |
| Viridian Therapeutics Inc | — | 93.4K | $1.83M | 0.5% | −$1.08M | Held |
| Xilio Therapeutics, Inc. | XLO | 106K | $891.3K | 0.3% | — | New |
| Carisma Therapeutics Inc | — | 1.47M | $47.9K | 0.0% | −$15.5K | Held |
| Neuphoria Therapeutics Inc. | NEUP | 10K | $40.8K | 0.0% | $1.91K | Held |
| TuHURA Biosciences, Inc./NV | HURA | 19.4K | $34.8K | 0.0% | $14.4K | Added$24.3K |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.